These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36182068)

  • 1. Inorganic nanoparticle-based advanced cancer therapies: Promising combination strategies.
    Amaldoss MJN; Yang JL; Koshy P; Unnikrishnan A; Sorrell CC
    Drug Discov Today; 2022 Dec; 27(12):103386. PubMed ID: 36182068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inorganic nanocarriers for siRNA delivery for cancer treatments.
    Kandasamy G; Maity D
    Biomed Mater; 2024 Jan; 19(2):. PubMed ID: 38181441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review.
    Varshosaz J; Taymouri S
    Curr Pharm Des; 2015; 21(29):4310-28. PubMed ID: 26323421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advancements in the Design of Nanodelivery Systems of siRNA for Cancer Therapy.
    Yadav DN; Ali MS; Thanekar AM; Pogu SV; Rengan AK
    Mol Pharm; 2022 Dec; 19(12):4506-4526. PubMed ID: 36409653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.
    Gandhi NS; Tekade RK; Chougule MB
    J Control Release; 2014 Nov; 194():238-56. PubMed ID: 25204288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy.
    Ashrafizadeh M; Zarrabi A; Hushmandi K; Hashemi F; Rahmani Moghadam E; Raei M; Kalantari M; Tavakol S; Mohammadinejad R; Najafi M; Tay FR; Makvandi P
    ACS Comb Sci; 2020 Dec; 22(12):669-700. PubMed ID: 33095554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in Treatment of Lung Cancer: Nanoparticle-based Drug and siRNA Delivery Systems.
    Gencer A; Duraloglu C; Ozbay S; Ciftci TT; Yabanoglu-Ciftci S; Arica B
    Curr Drug Deliv; 2021; 18(2):103-120. PubMed ID: 32748745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?
    Aghamiri S; Mehrjardi KF; Shabani S; Keshavarz-Fathi M; Kargar S; Rezaei N
    Nanomedicine (Lond); 2019 Aug; 14(15):2083-2100. PubMed ID: 31368405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
    Ku SH; Kim K; Choi K; Kim SH; Kwon IC
    Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticulate RNA delivery systems in cancer.
    Sharma A; Jha NK; Dahiya K; Singh VK; Chaurasiya K; Jha AN; Jha SK; Mishra PC; Dholpuria S; Astya R; Nand P; Kumar A; Ruokolainen J; Kesari KK
    Cancer Rep (Hoboken); 2020 Oct; 3(5):e1271. PubMed ID: 32729987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Cancer Therapy.
    Wang Y; Xie Y; Kilchrist KV; Li J; Duvall CL; Oupický D
    ACS Appl Mater Interfaces; 2020 Jan; 12(4):4308-4322. PubMed ID: 31939276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of co-delivery of nanoparticle-siRNA and anticancer agents in cancer therapy.
    Khelghati N; Soleimanpour Mokhtarvand J; Mir M; Alemi F; Asemi Z; Sadeghpour A; Maleki M; Samadi Kafil H; Jadidi-Niaragh F; Majidinia M; Yousefi B
    Chem Biol Drug Des; 2021 Apr; 97(4):997-1015. PubMed ID: 33458952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Delivery of siRNA Therapeutics using Ligand Mediated Biodegradable Polymeric Nanocarriers.
    Cho KS; Hong SJ; Ahn MH; Pal S; Choung PH; Sangshetti J; Arote RB
    Curr Pharm Des; 2018; 24(16):1788-1800. PubMed ID: 29962332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle-Based Combination Therapy for Cancer Treatment.
    Yhee JY; Son S; Lee H; Kim K
    Curr Pharm Des; 2015; 21(22):3158-66. PubMed ID: 26027570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.
    Miele E; Spinelli GP; Miele E; Di Fabrizio E; Ferretti E; Tomao S; Gulino A
    Int J Nanomedicine; 2012; 7():3637-57. PubMed ID: 22915840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNAi-based therapeutics and tumor targeted delivery in cancer.
    Kara G; Calin GA; Ozpolat B
    Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Environment-Responsive Lipid/siRNA Nanoparticles for Cancer Therapy.
    Lu ZR; Laney VEA; Hall R; Ayat N
    Adv Healthc Mater; 2021 Mar; 10(5):e2001294. PubMed ID: 33615743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
    Xu C; Liu W; Hu Y; Li W; Di W
    Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.